The Project

The goal of the PGRN-RIKEN collaboration is to accelerate pharmacogenomic discovery through collaborative research that makes use of well-phenotyped pharmacogenomic samples and genomewide or NextGen sequencing methods.  PGRN members who have DNA samples collected from patients on various drugs with associated therapeutic or adverse drug response phenotype may apply for a PGRN-RIKEN collaborative study.  The study enables collaboration with researcher at RIKEN Center for Integrative Medical Sciences (IMS).  The approved study will allow the samples to be genotyped on a genomewide genotyping platform or sequenced at no cost.  ​ 

<プロジェクトについて> 薬理遺伝学連合（PGRN）と理化学研究所（RIKEN）の連携研究（PGRN-RIKENコラボレーション）の目的は、詳細な表現型を有する薬理遺伝学研究サンプルと、ゲノムワイド関連解析や次世代シークエンサーによるシークエンス解析を共同研究を通じて実施することにより、薬理遺伝学における新たな発見を加速させていくことです。 種々の薬剤の治療効果や薬剤副作用などの表現型を有する患者さんのDNAサンプルを所有するPGRNのメンバーは、PGRNとRIKENの連携研究に応募することが可能です。共同研究は、理化学研究所統合生命医科学研究センター(RIKEN Center for Integrative Medical Sciences (IMS))の研究者と共同で実施されます。採択された研究課題は、ゲノムワイド関連解析、あるいはシークエンス解析における遺伝子型測定が無料で実施されます。

Proposal Submission

Each year, we have two rounds for submitting proposal. The PGRN-RIKEN Round 16 call for proposals is now closed.  Please visit here in future for future call. 

Future Meetings

Each year, we have two meeting, alternating between San Francisco and Tokyo.  
The next meeting is September 7th-8th 2017 in San Francisco, USA (click here to see the agenda). ​ Please register here by Friday, August 11.  There is a registration fee to attend the meeting, please visit the registration fee payment site here.  ​

News

We have 46 funded projects, 59 publications and over 56,000 DNA samples genotyped through this collaboration.

PGRN-RIKEN Projects

List of PGRN-RIKEN Projects

Publications

Full Publication List

Investigators

Team

Co-Leaders

Kathleen M. Giacomini, PhD
Michiaki Kubo, MD PhD
Mark J. Ratain, MD

Project Director

Sook Wah Yee, PhD

PGRN-Hub Project Director

Lawrence Lin, PhD

Steering Committee

Kathleen M. Giacomini, PhD
Mark J. Ratain, MD
Yoichiro Kamatani, MD, PhD
Michiaki Kubo, MD PhD
Yukihide Momozawa, DVM, PhD
Richard M. Weinshilboum, MD
Sook Wah Yee, PhD

Scientific Advisory Board

Nancy J. Cox, PhD
Dan M. Roden, MD
Tatsuhiko Tsunoda, MD, PhD
Rachel F. Tyndale, PhD

NIH Liaison

Kelly Filipski, PhD
Rochelle M. Long, PhD
Full Investigator List

History

The GAP-J (currently known as PGRN-RIKEN) was formally launched in the Spring of 2008. PGRN-RIKEN (previously known as GAP-J) was the brainchild of Dr. Yusuke Nakamura, Former Director of the RIKEN, and Drs. Mark J. Ratain and Kathleen M. Giacomini, Principal Investigators in the PGRN. After a series of discussions on the need to accelerate discoveries in pharmacogenomics, Drs. Nakamura, Ratain and Giacomini decided to try to utilize the complementary resources and expertise of the PGRN and the RIKEN (see GAP-J Letter of Intent). The PGRN has been successful assembling an abundance of DNA samples from well-phenotyped patients for specific drugs and drug combinations. The RIKEN focuses on high-throughput services for SNP analysis and has developed extraordinarily powerful genomewide technologies to identify genes that determine susceptibility to various disease and response to treatment. Together, the PGRN-RIKEN capitalizes on these strength to advance discoveries in personalized medicines and benefit global populations. Since 2012, Drs. Giacomini, Kubo and Ratain have co-lead the PGRN-RIKEN collaborative studies. This study was supported by the NIH Pharmacogenomics Research Network (PGRN)-RIKEN Global Alliance (U19 GM061390, 2010 – 2015).